Bacterial Delivery of RNAi for Cancer Treatment
Author Information
Author(s): Hermann Krühn, Andrea Lage
Primary Institution: Institute of Pathology, Charité Campus Mitte
Hypothesis
Can transkingdom RNAi (tkRNAi) effectively deliver therapeutic shRNA to reverse multidrug resistance in cancer cells?
Conclusion
The study demonstrates that tkRNAi can successfully modulate the expression of the ABCB1 gene in cancer cells, reversing their drug-resistant phenotype.
Supporting Evidence
- Fluorescence microscopy showed bacteria around treated cancer cells.
- Quantitative real-time RT PCR indicated a 70% down regulation of MDR1 mRNA after treatment.
- Western blot analysis confirmed reduced MDR1 protein levels in treated cells.
- Cytotoxicity assays demonstrated a 90% reversal of drug resistance in treated cells.
Takeaway
Scientists found a way to use bacteria to deliver special RNA that helps cancer cells respond better to drugs.
Methodology
The study involved transforming E. coli with shRNA expression vectors and co-incubating them with human gastric carcinoma cells to assess the effects on drug resistance.
Limitations
The optimal conditions for bacterial treatment may vary depending on the specific cancer cell line used.
Participant Demographics
Human gastric carcinoma cells were used in the experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website